Anthrax cost-effectiveness of therapy: Difference between revisions
Jump to navigation
Jump to search
Joao Silva (talk | contribs) No edit summary |
m (Bot: Removing from Primary care) |
||
| (2 intermediate revisions by 2 users not shown) | |||
| Line 17: | Line 17: | ||
[[Category:Zoonoses]] | [[Category:Zoonoses]] | ||
[[Category:Medical disasters]] | [[Category:Medical disasters]] | ||
[[Category:Emergency mdicine]] | |||
[[Category:Up-To-Date]] | |||
[[Category:Infectious disease]] | [[Category:Infectious disease]] | ||
[[Category:Dermatology]] | |||
[[Category:Pulmonology]] | |||
[[Category:Gastroenterology]] | |||
Latest revision as of 20:25, 29 July 2020
|
Anthrax Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Anthrax cost-effectiveness of therapy On the Web |
|
American Roentgen Ray Society Images of Anthrax cost-effectiveness of therapy |
|
Risk calculators and risk factors for Anthrax cost-effectiveness of therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Given the morbidity and mortality associated with Anthrax infection, and the low cost of safe and effective antibiotics, current pharmacotherapy to treat anthrax is relatively cost-effective.